Overview
- 14 inspections across 14 sites are on record.
- 1 Form 483 observation is attributed to this investigator.
- Most recent recorded activity is 2019-05-02.
At a glance
Inspections
14
Sites
14
Observations
1
Career since
Jan 2017
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Tanvex BioPharma USA, Inc | 2 May 2019 | Human Drugs | On file |
| Biocon Biologics Limited | 15 Feb 2019 | Human Drugs | On file |
| Boehringer Ingelheim Pharma GmbH and Co. KG | 21 Sep 2018 | Human Drugs | On file |
| QOL Medical LLC | 24 Aug 2018 | Human Drugs | On file |
| Boehringer Ingelheim RCV GmbH & CO KG | 17 Jul 2018 | Human Drugs | On file |
Sites inspected
Tanvex BioPharma USA, IncSan Diego, United States1 insp.
Biocon Biologics LimitedBengaluru, India1 insp.
Boehringer Ingelheim Pharma GmbH and Co. KGBiberach An Der Ris, Germany1 insp.
QOL Medical LLCClearwater, United States1 insp.
Boehringer Ingelheim RCV GmbH & CO KGVienna, Austria1 insp.
Co-investigators
Investigators who share inspections with this person.
Michael Shanks3 shared
Maria J Lopez- Barragan3 shared
Wayne E Seifert2 shared
Maria I Cruz-Fisher2 shared
Frances Namuswe1 shared
Lindsey J Brown1 shared
Thuy T Nguyen1 shared
Amanda L Fyles1 shared
Ruth A Moore1 shared
Zhong Li1 shared
Full investigator report
Get the verbatim findings behind Diane L Raccasi's 1 observation
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site